panel-4-navigating-the-regulatory-ip-nexus
17 May 2026VideosAmericasRolando Medina, Choate | MJ Edwards, Gilead Sciences | Manja Epping, Heuking | Lillian Hiett, Takeda Pharmaceuticals

WATCH: Navigating the regulatory-IP nexus—maximizing exclusivity in an evolving policy landscape

The intersection of regulatory strategy and intellectual property protection has become critical to maintaining market exclusivity. This panel examines how life sciences companies can adapt their IP strategies in response to shifting FDA guidance, biosimilar challenges, and evolving agency priorities.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
17 June 2026   A cancer diagnostics company has lost its bid to overturn a jury verdict in a major patent dispute that has also spawned parallel proceedings before the Federal Circuit and PTAB.
Americas
15 June 2026   Unanimous jury finds willful infringement, with the possibility of a trebled award and a much larger feud still to come.
Americas
12 June 2026   In a strong response to BioNTech, Moderna argues its next-gen vaccine is built on a fundamentally different design from the German biotech’s—setting up a scrap over whether a key patent should have been granted.